Chattanooga Team Achieves Highest Screening-to-Randomization Conversion Rate

A new paper in DiabeticMedicine, led by Dr Jonathan Goldney, a clinical fellow working under the supervision of Professor Dame Melanie J Davies DBE and in collaboration with colleagues across the Leicester Diabetes Centre, shows how a targeted multidisciplinary clinic can significantly improve outcomes for adults with early-onset type 2 diabetes. The evaluation demonstrates meaningful improvements in HbA1c, blood pressure and weight, alongside better use of evidence-based treatments. “By designing services that are flexible and focused on those at highest risk, we can deliver meaningful improvements in outcomes,” says lead author Dr Jonathan Goldney. This work reflects a true team effort across the Leicester Diabetes Centre and partner organisations, bringing together clinical, research and delivery expertise to design and evaluate a service that works in practice. Congratulations to everyone involved in this fantastic achievement. 🔗 https://lnkd.in/eH6vF-vh #DiabetesResearch #ClinicalInnovation #Type2Diabetes #HealthcareImprovement

Missed our live webinar on obesity clinical trial solutions? Watch the on-demand recording! Gain valuable insights and learn how IQVIA's innovative strategies accelerate patient recruitment, enhance site operations, and ensure robust, reliable data collection. Access the recording today. https://bit.ly/4j7JLOy

Early detection and innovative treatment strategies play a critical role in improving long term outcomes in women's gynecologic health. At Gazelle Clinical Research, we conduct specialized clinical trials focused on advancing the prevention, diagnosis, and management of cervical dysplasia and HPV related conditions. Our research integrates advanced diagnostic technologies and evidence based therapeutic approaches designed to support earlier intervention and more personalized care. Through scientific excellence and patient centered research, we are helping shape the future of cervical health by expanding access to innovative therapies and generating the evidence needed to improve outcomes for women worldwide. 🌐 https://lnkd.in/gkwCv8XH 📧 clinicaltrials@gazelleclinicalresearch.com 📞 (800) 918-6340 #CervicalHealth #HPVResearch #WomensHealth #ClinicalResearch #HealthcareInnovation

Three patient subtypes. Zero treatment history. One question: 𝗰𝗮𝗻 𝘆𝗼𝘂 𝗳𝗹𝗮𝗴 𝘁𝗵𝗲 𝗵𝗶𝗴𝗵𝗲𝘀𝘁-𝗿𝗶𝘀𝗸 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗯𝗲𝗳𝗼𝗿𝗲 𝘆𝗼𝘂 𝗸𝗻𝗼𝘄 𝗮𝗻𝘆𝘁𝗵𝗶𝗻𝗴 𝗮𝗯𝗼𝘂𝘁 𝘁𝗵𝗲𝗶𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗽𝗮𝘁𝗵? Working with synthetic EHR data (1,763 type 2 diabetes patients), I first let unsupervised clustering find natural patient groups. Three emerged: a mild majority, a small dyslipidemic subgroup, and a multimorbid group ⇾ older patients, high comorbidity burden, the ones who carry the most clinical risk if missed. Then came the harder question. Clustering after the fact is useful for research. But in practice, 𝘆𝗼𝘂 𝘄𝗮𝗻𝘁 𝘁𝗼 𝗸𝗻𝗼𝘄 𝗲𝗮𝗿𝗹𝘆, 𝗮𝘁 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝘃𝗶𝘀𝗶𝘁, 𝗯𝗲𝗳𝗼𝗿𝗲 𝗮𝗻𝘆 𝗺𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗵𝗶𝘀𝘁𝗼𝗿𝘆 𝗲𝘅𝗶𝘀𝘁𝘀. So I deliberately stripped the model down: no comorbidity index, no treatment data, no follow-up history. Just what's available on day one: age, labs, BMI. The result on a held-out test set: 𝟵𝟮% 𝗼𝗳 𝗺𝘂𝗹𝘁𝗶𝗺𝗼𝗿𝗯𝗶𝗱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗰𝗼𝗿𝗿𝗲𝗰𝘁𝗹𝘆 𝗳𝗹𝗮𝗴𝗴𝗲𝗱, using only baseline information. The model wasn't optimized for the best overall accuracy, it was optimized to catch the group that matters most clinically. That distinction, choosing what to optimize for not just how, is where a biotech background changes the questions you ask a dataset. #DataScience #MachineLearning #HealthcareAnalytics #RealWorldEvidence

A liver assessment is only valuable if it helps answer one question: What should I do next? For clinicians managing patients with MASLD/MASH, every assessment has the potential to influence the next step in care, whether that means: • Referring a patient for specialist evaluation • Prioritising further diagnostic assessment • Initiating or intensifying lifestyle interventions • Monitoring disease progression over time • Identifying patients who may benefit from emerging therapies LIVERFASt™ was designed to support these everyday clinical decisions by providing biopsy-aligned fibrosis staging, along with steatosis and activity assessment, helping translate laboratory data into clinically meaningful insights. Because clinicians don't just need results. They need information that supports confident decisions and better patient care. Learn more about the clinical evidence behind LIVERFASt™: https://zurl.co/TXJaY #PhysicianPerspective #ClinicalDecisionMaking #MASLD #MASH #LIVERFASt #ClinicalPathways #RiskStratification #LiverHealth #ClinicalEvidence #Fibronostics

Conclusion: There has been an increasing trend toward the use of PSMA PET/CT for staging mCSPC in recent years, identifying a population with more favourable disease characteristics and a more favourable prognosis. This shift in patient characteristics, driven by stage migration (the Will Rogers phenomenon), influences clinical management by enabling more refined patient selection for conservative or targeted therapies. Consequently, accounting for lead-time and selection bias is essential when comparing survival outcomes in the PSMA PET/CT era.

ICYMI: article published in the Canadian Medical Association Journal last week, outlining pros and cons of lecanemab, the first disease-modifying drug available for people in the early stages of Alzheimer’s disease.

$50B in RHTP funding is on the table. AI diagnostics at the point of care is exactly the kind of project that wins these applications. Breakdown below 👇 #RuralHealth #DiabeticRetinopathy #ValueBasedCare #PrimaryCare 

Successful implementation will depend on workflow integration, staff training, quality execution, and measurable outcomes. Autonomous point-of-care diagnostics can be a practical way for rural primary care settings to close diabetic eye care gaps without adding unnecessary burden to patients or clinics.

Over 60% of patients with diabetes skip their annual diabetic eye exam. In rural America, that gap is often even wider because the nearest retina specialist can be hours away, transforming a routine check-up into a full day off work. That’s where the $50B Rural Health Transformation Program (RHTP) comes in, helping you close that care gap. Several states are already directing this funding to chronic disease prevention and technology innovation, exactly where autonomous, point-of-care AI diagnostics can fit. Best of all, RHTP funding covers the setup and subscription rather than the clinical exam itself.  Individual screenings are billed separately under CPT code 92229, turning a grant-funded initiative into a self-funding revenue engine. One caveat: RHTP is a competitive, scored application through your state - not an entitlement. The states reward high-impact projects that plug into existing primary care workflows. Given that, it's worth building a case that shows clear, measurable impact. We broke down how to position AI diagnostics against your state's outcome targets, navigate the RFP process, and improve your HEDIS and MIPS Measure 117 scores. You can read the full analysis here: https://lnkd.in/d6cFB_Ga